CN114773416A - NADH protectant and its prepn - Google Patents
NADH protectant and its prepn Download PDFInfo
- Publication number
- CN114773416A CN114773416A CN202210340349.4A CN202210340349A CN114773416A CN 114773416 A CN114773416 A CN 114773416A CN 202210340349 A CN202210340349 A CN 202210340349A CN 114773416 A CN114773416 A CN 114773416A
- Authority
- CN
- China
- Prior art keywords
- nadh
- protectant
- solution
- buffer
- reducing agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 title claims abstract description 70
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 title claims abstract description 70
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract description 41
- 239000003638 chemical reducing agent Substances 0.000 claims abstract description 21
- 239000003223 protective agent Substances 0.000 claims abstract description 21
- 239000007853 buffer solution Substances 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims description 31
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 18
- 229940098773 bovine serum albumin Drugs 0.000 claims description 18
- 239000000872 buffer Substances 0.000 claims description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 239000008367 deionised water Substances 0.000 claims description 5
- 229910021641 deionized water Inorganic materials 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 239000006173 Good's buffer Substances 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 239000007983 Tris buffer Substances 0.000 claims description 3
- 235000001727 glucose Nutrition 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000004302 potassium sorbate Substances 0.000 claims description 3
- 229940069338 potassium sorbate Drugs 0.000 claims description 3
- 235000010241 potassium sorbate Nutrition 0.000 claims description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 abstract description 14
- 108090000790 Enzymes Proteins 0.000 abstract description 14
- 238000002360 preparation method Methods 0.000 abstract description 13
- 238000006243 chemical reaction Methods 0.000 abstract description 11
- 230000001681 protective effect Effects 0.000 abstract description 6
- 238000006479 redox reaction Methods 0.000 abstract description 3
- 230000009467 reduction Effects 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 8
- 230000014759 maintenance of location Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 5
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 5
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 102000005548 Hexokinase Human genes 0.000 description 2
- 108700040460 Hexokinases Proteins 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- FYKBJIJHQDFVCI-KVQBGUIXSA-N (2S,5R,6R)-2,6-diamino-5,7-dihydroxyheptanoic acid Chemical compound N[C@H](CO)[C@H](O)CC[C@H](N)C(O)=O FYKBJIJHQDFVCI-KVQBGUIXSA-N 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101000869664 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) FAD-dependent catabolic D-arginine dehydrogenase DauA Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- VFRROHXSMXFLSN-SLPGGIOYSA-N aldehydo-D-glucose 6-phosphate Chemical group OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O VFRROHXSMXFLSN-SLPGGIOYSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The invention provides a NADH protective agent and a preparation method thereof, wherein the NADH protective agent comprises the following components: buffer solution, reducing agent, ethylene glycol and BSA; wherein the pH value of the NADH protective agent is 9.0-10.0. In the invention, the reducing agent is used for protecting NADH, and when the redox reaction occurs, the reducing agent participates in the reaction, and the NADH keeps stable and does not participate in the reaction, so that the aim of protecting the NADH is fulfilled by the method. The protective agent components with strong reduction, good stability and low price are selected, thereby solving the problems of high cost and poor stability of the protective system. By completely abandoning the idea of enzyme protective agent, the problem of enzyme interference in practical use is avoided.
Description
Technical Field
The invention belongs to the field of biological agents, and particularly relates to an NADH protective agent and a preparation method thereof.
Background
The NADH protection system commonly used at present is a glucose-6-phosphate dehydrogenase system, the main components of the system are glucose, phosphate, G-6-PDH, HK (hexokinase), and the main principle is as follows: NAD + is the oxidation form of NADH, glucose forms glucose-6-phosphate under the catalysis of hexokinase, then glucose-6-phosphate forms phosphogluconolactone under the action of glucose-6-phosphate dehydrogenase, and NAD + is reduced to NADH, thereby maintaining the stability of the relative concentration of NADH. However, this system has the following disadvantages in practical use because it uses two enzymes: 1. the cost is high: the two enzymes needed in the system have higher market price, and the cost is increased in practical use; 2. poor stability: since the enzyme itself is an unstable substance, the enzyme itself is decomposed and denatured during long-term storage, and finally inactivated, so that the protective ability of the protective system is weakened or ineffective. 3. Interfering with the reaction. Because the glucose-6-phosphate dehydrogenase system is essentially protected by reducing NAD + to NADH. In the reaction involving NADH, if the amount of enzyme in the protection system is not appropriate, the reaction of NADH to NAD + is interfered, and the final result is interfered.
Disclosure of Invention
In view of this, the invention provides an NADH protectant and a preparation method thereof, and aims to provide an NADH protectant with low preparation cost and good protection effect, and avoid the problem of enzyme interference in practical use.
In order to achieve the above object, the present invention provides a NADH protectant, comprising: buffer solution, reducing agent, ethylene glycol and BSA;
wherein the pH value of the NADH protective agent is 9.0-10.0.
Optionally, the reducing agent comprises at least one of glucose, mannitol, glycerol, and potassium sorbate.
Optionally, the concentration of the reducing agent is 30g/L to 50 g/L.
Optionally, in the NADH protectant, the concentration of the ethylene glycol is 200 ml/L-400 ml/L.
Optionally, in the NADH protectant, the concentration of BSA is 0.5 g/L-2 g/L.
Optionally, the buffer comprises any one of Tris buffer, PBS buffer, and Good's buffer.
Optionally, the concentration of the buffer solution is 50 mmol/L-100 mmol/L.
In addition, the invention provides a preparation method of the NADH protectant, and the preparation method of the NADH protectant comprises the following steps:
adding a buffer solution into deionized water to obtain a first solution;
adding a reducing agent, ethylene glycol and BSA (bovine serum albumin) into the first solution in sequence to obtain a second solution;
and adjusting the pH value of the second solution to 9.0-10 to obtain the NADH protective agent.
In the invention, other reducing substances are used for protecting NADH, and when the redox reaction occurs, the other reducing substances participate in the reaction, while NADH is kept stable and does not participate in the reaction, so that the purpose of protecting NADH is achieved by the method. The protective agent components with strong reduction type, good stability and low price are selected, thereby solving the problems of high cost and poor stability of the protective system. By completely abandoning the idea of enzyme protective agent, the problem of enzyme interference in practical use is avoided. At the same time, a high pH is used to stabilize NADH.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, it is obvious that the drawings in the following description are only some embodiments of the present invention, and for those skilled in the art, other related drawings can be obtained according to the drawings without creative efforts.
FIG. 1 is a flow chart of the preparation method of the NADH protectant provided by the invention.
The implementation, functional features and advantages of the present invention will be further described with reference to the accompanying drawings.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention more apparent, the technical solutions of the embodiments of the present invention will be clearly and completely described below. It is to be understood that the described embodiments are merely a few embodiments of the invention, and not all embodiments.
It should be noted that those whose specific conditions are not specified in the examples were performed according to the conventional conditions or the conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially. In addition, the meaning of "and/or" appearing throughout includes three juxtapositions, exemplified by "A and/or B" including either A or B or both A and B. In addition, technical solutions between various embodiments may be combined with each other, but must be realized by a person skilled in the art, and when the technical solutions are contradictory or cannot be realized, such a combination should not be considered to exist, and is not within the protection scope of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The commonly used protection system is glucose-6-phosphate dehydrogenase system, but because the system uses two enzymes, the glucose-6-phosphate dehydrogenase system can achieve the protection purpose by reducing NAD + to NADH in the practical application. In the reaction involving NADH, if the amount of enzyme in the protection system is not appropriate, the reaction of NADH to NAD + is interfered, and the final result is interfered.
In view of the above, the present invention provides a NADH protectant, and the following is an embodiment of the NADH protectant provided by the present invention.
The NADH protectant comprises the following components:
buffer solution, reducing agent, ethylene glycol and BSA; wherein the pH value of the NADH protective agent is 9.0-10.0.
In the invention, other reducing substances are used for protecting NADH, and during the oxidation-reduction reaction, the reducing substances in the reducing agent participate in the reaction, while NADH keeps stable and does not participate in the reaction, so that the aim of protecting NADH is achieved by the method. The reducing agent component with strong reduction type, good stability and low price is selected, thereby solving the problems of high cost and poor stability of an NADH protection system. By completely abandoning the idea of enzyme protective agent, the problem of enzyme interference in practical use is avoided. At the same time, a high pH is used to stabilize NADH.
In some embodiments, the buffer includes any one of Tris buffer, phosphate buffer (PBS buffer), and zwitterionic buffer (Good's buffer), and the use of the above buffer can further improve the stability of the pH environment of the solvent. Specifically, the concentration of any one of the above buffers is 50mmol/L to 100 mmol/L.
In some embodiments, the reducing agent comprises at least one of glucose, mannitol, glycerol, and potassium sorbate. The adoption of the reducing substance avoids the oxidative damage to NADH and improves the storage stability of NADH.
In some embodiments, the concentration of the ethylene glycol is 200ml/L to 400 ml/L; the concentration of BSA is 0.5 g/L-2 g/L, and the ethylene glycol and BSA are used for protecting the stability of NADH and simultaneously maintaining the stability of the relative concentration of NADH.
In addition, the invention also provides a preparation method of the NADH protective agent, and the preparation method of the NADH protective agent comprises the following steps:
s10, adding a buffer solution into deionized water to obtain a first solution;
s20, sequentially adding a reducing agent, ethylene glycol and BSA (bovine serum albumin) into the first solution to obtain a second solution;
s30, adjusting the pH value of the second solution to 9.0-10 to obtain the NADH protective agent.
The technical solutions of the present invention are further described in detail with reference to the following specific examples, which should be understood as merely illustrative and not limitative.
Examples 1 to 4
Examples 1-4 provide respective NADH protectants, the specific components of which are shown in Table 1:
TABLE 1 EXAMPLES 1-4 ingredients and final concentrations of NADH protectant
Embodiments 1 to 4 also provide a preparation method of the NADH protectant, which comprises the following specific operation methods:
s10, adding a buffer solution into deionized water to obtain a first solution;
s20, sequentially adding a reducing agent, ethylene glycol and BSA (bovine serum albumin) into the first solution to obtain a second solution;
s30, adjusting the pH value of the second solution to 9.0-10.0 to obtain the NADH protective agent.
Wherein, the preparation method comprises the steps of preparing the materials according to the table.
Examples 5 to 8
Examples 5 to 8 provide respective NADH protectants, the specific components of which are shown in Table 2:
TABLE 2 ingredients and final concentrations of NADH protectors in examples 5-8
Embodiments 5 to 8 further provide a preparation method of the NADH protectant, the specific operation method comprising:
s10, adding a buffer solution into deionized water to obtain a first solution;
s20, sequentially adding a reducing agent, ethylene glycol and BSA (bovine serum albumin) into the first solution to obtain a second solution;
s30, adjusting the pH value of the second solution to 9.0-10.0 to obtain the NADH protective agent.
Wherein, the preparation method comprises the steps of preparing the materials according to the table.
Comparative example 1
This comparative example provides an antibody preservative solution that is substantially identical to the composition of example 1, except that the reducing agent is not included.
Comparative example 2
This comparative example provides an antibody preservative solution substantially identical to the composition of example 1, except that it does not contain ethylene glycol.
Comparative example 3
This comparative example provides an antibody preservative solution that is substantially identical to the composition of example 1, except that BSA is not included.
Test example 1
1. Sucking blood type Lewis A antibodies by a graduated pipette, adding the blood type Lewis A antibodies into NADH protective solutions respectively added in examples 1-8 and comparative example 1, ensuring the concentration of the blood type Lewis A antibodies to be 500 mug/mL, preserving one part of blood type Lewis A antibodies at 4 ℃, testing the titer of the other part of blood type Lewis A antibodies, and testing different antibody protective solutions to ensure that the initial titer is 1: 512.
2. after one month, taking out the part preserved at 4 ℃, detecting the titer again according to the steps, calculating the ratio of the titer at the last time to the titer at the previous time to obtain the activity retention rate, meanwhile, preserving the part which is not subjected to the experiment again at 4 ℃, repeatedly freezing and thawing the part, taking out the part again after two months, and performing the experiment test of the titer detection, wherein the ratio of the detected titer to the initial titer is the activity retention rate, and the test results are shown in table 3.
TABLE 3 Titer test results
| Activity retention after one month (%) | Activity retention after two months (%) | |
| Example 1 | 100 | 90 |
| Example 2 | 100 | 90 |
| Example 3 | 100 | 100 |
| Example 4 | 100 | 90 |
| Example 5 | 100 | 80 |
| Example 6 | 100 | 80 |
| Example 7 | 100 | 100 |
| Example 8 | 100 | 80 |
| Comparative example 1 | 50 | 10 |
| Comparative example 2 | 50 | 25 |
| Comparative example 3 | 50 | 25 |
As shown in table 3, in examples 1 to 8, compared to comparative example 1, the reducing agent is used as the protective agent, and compared to comparative example 2, the antioxidant is added, so that the activity retention rate of the antibody after being stored at 4 ℃ for one month is 100%, and the activity retention rate after repeated freeze thawing is more than 50%. Meanwhile, when the pH value of DADH is 9 and the protective agent contains sodium caseinate, the activity retention rate of the antibody is 100% after repeated freeze thawing.
The above are only preferred embodiments of the present invention, and do not limit the scope of the present invention, and it is obvious to those skilled in the art that various modifications and variations can be made in the present invention. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention shall be included in the scope of the present invention.
Claims (8)
1. An NADH protectant, wherein the NADH protectant comprises a buffer, a reducing agent, ethylene glycol, and BSA;
wherein the pH value of the NADH protective agent is 9.0-10.0.
2. The NADH protectant of claim 1, wherein said reducing agent comprises at least one of glucose, mannitol, glycerol, and potassium sorbate.
3. The NADH protectant according to claim 1, wherein the reducing agent is present in a concentration of 30g/L to 50 g/L.
4. The NADH protectant of claim 1, wherein said glycol is present in a concentration of 200ml/L to 400ml/L in said NADH protectant.
5. The NADH protectant of claim 1, wherein the BSA concentration is 0.5g/L to 2 g/L.
6. The NADH protectant according to claim 1, wherein the buffer comprises any one of Tris buffer, PBS buffer, and Good's buffer.
7. The NADH protectant of claim 6, wherein the buffer has a concentration of 50mmol/L to 100 mmol/L.
8. A method for preparing a NADH protectant according to any of claims 1-7, comprising the steps of:
adding a buffer solution into deionized water to obtain a first solution;
adding a reducing agent, ethylene glycol and BSA (bovine serum albumin) into the first solution in sequence to obtain a second solution;
and adjusting the pH value of the second solution to 9.0-10 to obtain the NADH protective agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210340349.4A CN114773416A (en) | 2022-04-01 | 2022-04-01 | NADH protectant and its prepn |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210340349.4A CN114773416A (en) | 2022-04-01 | 2022-04-01 | NADH protectant and its prepn |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114773416A true CN114773416A (en) | 2022-07-22 |
Family
ID=82426424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210340349.4A Pending CN114773416A (en) | 2022-04-01 | 2022-04-01 | NADH protectant and its prepn |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114773416A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1512326A (en) * | 1975-04-21 | 1978-06-01 | Hoffmann La Roche | Process for the stabilisation of reduced beta-nicotinamide-adenosinedinucleotide |
| EP0009222A2 (en) * | 1978-09-20 | 1980-04-02 | American Monitor Corp. | The stabilization of working reagent solutions containing NADH, NADPH, and/or enzymes, and the use of such stabilized reagents in enzyme or substrate assays |
| CN1778953A (en) * | 2004-11-23 | 2006-05-31 | 苏州艾杰生物科技有限公司 | Determination of inorganic phosphorus and its diagnostic reagent kit |
| CN102994612A (en) * | 2012-12-24 | 2013-03-27 | 北京利德曼生化股份有限公司 | Liquid monomer reagent for determining content of ammonia in blood serum, preparation method and application thereof |
| CN105002263A (en) * | 2015-07-28 | 2015-10-28 | 中生北控生物科技股份有限公司 | Reduced coenzyme composite agent and application thereof |
| CN105420344A (en) * | 2015-12-12 | 2016-03-23 | 山东博科生物产业有限公司 | Stable serum-potassium detection reagent with high anti-interference capability and detection method |
-
2022
- 2022-04-01 CN CN202210340349.4A patent/CN114773416A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1512326A (en) * | 1975-04-21 | 1978-06-01 | Hoffmann La Roche | Process for the stabilisation of reduced beta-nicotinamide-adenosinedinucleotide |
| EP0009222A2 (en) * | 1978-09-20 | 1980-04-02 | American Monitor Corp. | The stabilization of working reagent solutions containing NADH, NADPH, and/or enzymes, and the use of such stabilized reagents in enzyme or substrate assays |
| CN1778953A (en) * | 2004-11-23 | 2006-05-31 | 苏州艾杰生物科技有限公司 | Determination of inorganic phosphorus and its diagnostic reagent kit |
| CN102994612A (en) * | 2012-12-24 | 2013-03-27 | 北京利德曼生化股份有限公司 | Liquid monomer reagent for determining content of ammonia in blood serum, preparation method and application thereof |
| CN105002263A (en) * | 2015-07-28 | 2015-10-28 | 中生北控生物科技股份有限公司 | Reduced coenzyme composite agent and application thereof |
| CN105420344A (en) * | 2015-12-12 | 2016-03-23 | 山东博科生物产业有限公司 | Stable serum-potassium detection reagent with high anti-interference capability and detection method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5348852A (en) | Diagnostic and therapeutic compositions | |
| CN102141568A (en) | Stable liquid single-reagent blood sugar kit | |
| AU621993B2 (en) | Stabilization of oxidase enzyme-based test strips | |
| WO2013016379A4 (en) | Reagents for electrochemical test strips | |
| JPH08187095A (en) | Stabilizing method of cholesterol oxidase | |
| CN114773416A (en) | NADH protectant and its prepn | |
| EP0484133A2 (en) | Method for measuring bilirubin | |
| CN108690868B (en) | Adenosine deaminase determination kit and determination method thereof | |
| CN104611319B (en) | A kind of method improving liquid fructose amino-acid oxidase enzyme heat stability | |
| GB893301A (en) | Colorimetric test for serum enzymes | |
| JPH0670798A (en) | Reagent composition for ulic acid measurement | |
| Holland et al. | Chemical reactivity at the catalytic sites of aspartic β-semialdehyde dehydrogenase and glyceraldehyde 3-phosphate dehydrogenase | |
| EP0117032A1 (en) | Rapid analysis of ethanol in body fluids | |
| Callewaert et al. | Purification and properties of 4-aminobutanal dehydrogenase from a Pseudomonas species | |
| JPS5836954B2 (en) | Enzyme stabilizer | |
| Hemphill et al. | 5′-Adenosine Monophosphate Aminohydrolase: EVIDENCE FOR ANOMALOUS SUBSTRATE SATURATION KINETICS AT LOW ENZYME CONCENTRATIONS | |
| Graubard | Uterine respiration, cytochrome oxidase and copper | |
| Chen et al. | Alkylamidase of sheep liver | |
| CN114480567B (en) | Anti-heparin interference creatine kinase biochemical detection reagent | |
| CN114480561B (en) | Superoxide dismutase detection kit | |
| JP4503151B2 (en) | Urea nitrogen measurement method and reagent for measurement | |
| CN112646027B (en) | Preparation method of hemoglobin control freeze-dried product | |
| JPH0231954B2 (en) | KOSONOANTEIKAZAIOYOBIKOSOHOZONHOHO | |
| WO1995022602A1 (en) | Isoenzyme calibrator/control products | |
| JP3522307B2 (en) | Liquid reagent composition for measuring inorganic phosphorus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |